行情

MDWD

MDWD

Mediwound
NASDAQ

实时行情|Nasdaq Last Sale

3.030
+0.030
+1.00%
休市 16:00 01/17 EST
开盘
3.010
昨收
3.000
最高
3.040
最低
3.010
成交量
5.55万
成交额
--
52周最高
6.09
52周最低
2.548
市值
8,235.19万
市盈率(TTM)
7.11
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

MDWD 新闻

  • MediWound Expands its Distribution Agreement with GENFA MEDICA SA to Market NexoBrid in Ukraine and the Baltic States
  • GlobeNewswire.4天前
  • BARDA to procure NexoBrid for emergency response
  • Seeking Alpha - Article.01/06 11:56
  • MediWound and Vericel's NexoBrid Receives $16.5M of Orders from the US Biomedical Advanced Research and Development Authority for Emergency Stockpiling
  • Benzinga.01/06 11:36
  • BARDA Initiates the Procurement of NexoBrid for Emergency Response
  • GlobeNewswire.01/06 11:30

更多

所属板块

制药
+0.13%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

MDWD 简况

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.
展开

Webull提供Mediwound Ltd的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。